Relmada Therapeutics Inc (RLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,857 | 4,092 | 5,396 | 44,443 | 2,495 |
| Marketable Securities | 41,052 | 92,232 | 142,927 | 167,466 | 114,596 |
| Receivables | N/A | N/A | 512 | 86 | 80 |
| TOTAL | $45,796 | $97,509 | $152,870 | $223,298 | $118,074 |
| Non-Current Assets | |||||
| PPE Net | N/A | N/A | N/A | N/A | 1 |
| Other Non-Current Assets | 22 | 43 | 35 | 28 | 111 |
| TOTAL | $22 | $43 | $35 | $28 | $113 |
| Total Assets | $45,818 | $97,552 | $152,905 | $223,326 | $118,186 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,131 | 3,506 | 5,262 | 11,193 | 8,347 |
| Accrued Expenses | 6,161 | 8,689 | 7,207 | 3,868 | 4,257 |
| TOTAL | $10,291 | $12,195 | $12,469 | $15,061 | $12,604 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 5 | 0 | 0 | 0 | 0 |
| TOTAL | $5 | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $10,296 | $12,195 | $12,469 | $15,061 | $12,604 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 33,192 | 30,174 | 30,099 | 29,369 | 16,746 |
| Common Shares | 30 | 30 | 30 | 28 | 16 |
| Retained earnings | -640,882 | -560,903 | -462,111 | -305,067 | -179,315 |
| TOTAL | $35,522 | $85,357 | $140,436 | $208,265 | $105,583 |
| Total Liabilities And Equity | $45,818 | $97,552 | $152,905 | $223,326 | $118,186 |